

# Consolidated Financial Statements

## Consolidated Balance Sheet

(Millions of yen)

	FY2022 (As of June 30, 2023)	FY2023 (As of June 30, 2024)
<b>Assets</b>		
<b>Current assets</b>		
Cash and deposits	98,399	96,334
Notes and accounts receivable, trade and contract assets	83,538	103,261
Merchandise and finished goods	6,140	6,426
Work in process	36,485	40,911
Raw materials and supplies	19,335	22,162
Other	11,903	10,224
Allowance for doubtful accounts	(521)	(472)
Total current assets	255,280	278,846
<b>Non-current assets</b>		
<b>Property, plant and equipment</b>		
Buildings and structures	87,062	98,606
Accumulated depreciation	(61,146)	(64,288)
Buildings and structures, net	25,915	34,318
Machinery, equipment and vehicles	84,162	91,002
Accumulated depreciation	(63,763)	(66,142)
Machinery, equipment and vehicles, net	20,399	24,860
Tools, furniture and fixtures	14,840	15,272
Accumulated depreciation	(13,099)	(12,940)
Tools, furniture and fixtures, net	1,741	2,332
Land	8,245	8,285
Leased assets	5,981	6,202
Accumulated depreciation	(2,311)	(2,506)
Leased assets, net	3,670	3,696
Construction in progress	9,617	6,254
Total property, plant and equipment	69,588	79,745
<b>Intangible assets</b>		
Leased assets	23	24
Software	1,746	2,998
Other	2,568	2,381
Total intangible assets	4,336	5,403
<b>Investments and other assets</b>		
Investment securities	10,151	10,307
Retirement benefit asset	940	1,158
Deferred tax assets	6,245	5,860
Other	8,962	8,173
Allowance for doubtful accounts	(2,030)	(839)
Total investments and other assets	24,269	24,659
Total non-current assets	98,193	109,807
<b>Total assets</b>	<b>353,474</b>	<b>388,653</b>

(Millions of yen)

	FY2022 (As of June 30, 2023)	FY2023 (As of June 30, 2024)
<b>Liabilities</b>		
<b>Current liabilities</b>		
Notes and accounts payable, trade	47,336	46,340
Short-term borrowings	11,878	12,967
Lease liabilities	898	958
Income taxes payable	2,328	3,378
Contract liabilities	22,685	26,624
Provision for bonuses	5,072	6,954
Provision for bonuses for directors (and other officers)	368	396
Provision for product warranties	1,726	1,750
Provision for loss on orders received	313	884
Other	14,149	16,126
Total current liabilities	106,754	116,378
<b>Non-current liabilities</b>		
Long-term borrowings	30,080	33,794
Lease liabilities	3,037	2,972
Deferred tax liabilities	195	473
Retirement benefit liability	7,414	5,758
Provision for share awards for directors (and other officers)	311	470
Asset retirement obligations	409	414
Other	420	667
Total non-current liabilities	41,867	44,548
<b>Total liabilities</b>	<b>148,620</b>	<b>160,926</b>
<b>Net Assets</b>		
<b>Shareholders' equity</b>		
Share capital	20,873	20,873
Capital surplus	3,912	3,912
Retained earnings	160,563	175,417
Treasury shares	(345)	(257)
Total shareholders' equity	185,003	199,945
<b>Accumulated other comprehensive income</b>		
Valuation difference on available-for-sale securities	2,036	1,928
Foreign currency translation adjustment	12,721	18,696
Remeasurements of defined benefit plans	(1,547)	(140)
Total accumulated other comprehensive income	13,209	20,485
<b>Non-controlling interests</b>	<b>6,641</b>	<b>7,297</b>
<b>Total net assets</b>	<b>204,853</b>	<b>227,727</b>
<b>Total liabilities and net assets</b>	<b>353,474</b>	<b>388,653</b>

## Consolidated Financial Statements

### Consolidated Statements of Income

(Millions of yen)

	FY2022 (July 1, 2022-June 30, 2023)	FY2023 (July 1, 2023-June 30, 2024)
<b>Net sales</b>	227,528	261,115
<b>Cost of sales</b>	160,366	180,455
<b>Gross profit</b>	67,162	80,660
<b>Selling, general and administrative expenses</b>		
Selling expenses	17,893	20,840
General and administrative expenses	29,324	30,050
Total selling, general and administrative expenses	47,217	50,890
<b>Operating profit</b>	19,946	29,771
<b>Non-operating income</b>		
Interest income	394	522
Dividend income	429	574
Subsidy income	320	340
Share of profit of entities accounted for using equity method	2,661	495
Other	1,259	1,060
Total non-operating income	5,063	2,989
<b>Non-operating expenses</b>		
Interest expenses	441	507
Foreign exchange losses	574	1,386
Commission for syndicated loans	287	—
Other	826	1,081
Total non-operating expenses	2,128	2,975
<b>Ordinary profit</b>	22,880	29,785
<b>Extraordinary income</b>		
Gain on sales of investment securities	—	155
Gain on sales of non-current assets	153	94
Total extraordinary income	153	249
<b>Extraordinary losses</b>		
Impairment losses	2,311	217
Loss on valuation of investment securities	—	303
Total extraordinary losses	2,311	520
<b>Profit before income taxes</b>	20,722	29,515
<b>Income taxes - current</b>	6,100	7,401
<b>Income taxes - deferred</b>	542	565
<b>Total income taxes</b>	6,642	7,966
<b>Profit</b>	14,080	21,549
<b>Profit (loss) attributable to non-controlling interests</b>	(89)	1,316
<b>Profit attributable to owners of parent</b>	14,169	20,233

### Consolidated Statements of Comprehensive Income

(Millions of yen)

	FY2022 (July 1, 2022-June 30, 2023)	FY2023 (July 1, 2023-June 30, 2024)
<b>Profit</b>	14,080	21,549
<b>Other comprehensive income</b>		
Valuation difference on available-for-sale securities	602	(121)
Foreign currency translation adjustment	639	5,600
Remeasurements of defined benefit plans, net of tax	154	1,405
Share of other comprehensive income of entities accounted for using equity method	(59)	655
Total other comprehensive income	1,336	7,539
Comprehensive income	15,415	29,088
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	15,357	27,509
Comprehensive income attributable to non-controlling interests	59	1,579

### Consolidated Statements of Cash Flows

(Millions of yen)

	FY2022 (July 1, 2022-June 30, 2023)	FY2023 (July 1, 2023-June 30, 2024)
<b>Cash flows from operating activities</b>		
Profit before income taxes	20,722	29,515
Depreciation	8,245	9,181
Impairment losses	2,311	217
Loss (gain) on valuation of investment securities	—	303
Increase (decrease) in allowance for doubtful accounts	36	(1,358)
Increase (decrease) in provision for bonuses	(869)	1,639
Increase (decrease) in retirement benefit liability	238	319
Increase (decrease) in provision for share awards for directors (and other officers)	39	159
Increase (decrease) in provision for product warranties	328	(65)
Increase (decrease) in provision for loss on orders received	297	571
Interest and dividend income	(822)	(1,095)
Interest expenses	441	507
Subsidy income	(321)	(340)
Share of loss (profit) of entities accounted for using equity method	(2,661)	(495)
Loss (gain) on sale of investment securities	—	(155)
Loss (gain) on sale of non-current assets	(153)	(94)
Decrease (increase) in trade receivables	3,629	(15,524)
Decrease (increase) in inventories	(12,530)	(6,904)
Increase (decrease) in trade payables	(8,418)	(2,981)
Increase (decrease) in net contract liabilities	(2,725)	2,113
Increase (decrease) in accrued consumption taxes	(913)	71
Increase (increase) in accrued consumption taxes	(40)	1,496
Other	2,540	4,768
<b>Subtotal</b>	<b>9,373</b>	<b>21,851</b>
Interest and dividends received	1,026	1,601
Interest paid	(400)	(535)
Income taxes paid	(8,987)	(5,756)
<b>Cash flows from operating activities</b>	<b>1,011</b>	<b>17,162</b>
<b>Cash flows from investing activities</b>		
Payments into time deposits	(25,578)	(25,562)
Proceeds from withdrawal of time deposits	25,495	25,214
Purchase of property, plant and equipment and intangible assets	(16,311)	(19,881)
Proceeds from sale of property, plant and equipment and intangible assets	435	128
Proceeds from sale of investment securities	—	291
Subsidy income	321	340
Other	(36)	(53)
<b>Cash flows from investing activities</b>	<b>(15,673)</b>	<b>(19,524)</b>
<b>Cash flows from financing activities</b>		
Net increase (decrease) in short-term borrowings	1,483	(459)
Proceeds from long-term borrowings	7,300	12,800
Repayments of long-term borrowings	(6,368)	(7,722)
Repayments of lease liabilities	(879)	(1,078)
Dividends paid	(6,115)	(5,375)
Purchase of treasury shares	(1)	(1)
Dividends paid to non-controlling interests	(858)	(949)
Other	0	—
<b>Cash flows from financing activities</b>	<b>(5,438)</b>	<b>(2,784)</b>
<b>Effect of exchange rate change on cash and cash equivalents</b>	<b>312</b>	<b>2,369</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(19,788)</b>	<b>(2,776)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>107,106</b>	<b>87,317</b>
<b>Cash and cash equivalents at end of period</b>	<b>87,317</b>	<b>84,541</b>